

Drug Monograph

Drug Name: **Absorica LD™ (isotretinoin) capsules**
 Drug Class: **Retinoid**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Absorica LD is available in 8 mg, 16 mg, 24 mg, and 32 mg capsules.

Manufacturer: Ohm Laboratories Inc. New Brunswick, NJ 08901.

Indications: Absorica LD is a retinoid indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Absorica LD is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.

Costs: \$1,063 per 30 days of 8 and 16 mg. \$1,144 per 30 days of 24 and 32 mg.
 Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends prior authorization status for this product.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Jennifer Anderson PharmD, BCPS
 Date: February 27, 2020